Forte Biosciences (FBRX) Stock Price, Quote, News & History

Q: What sector and industry does Forte Biosciences (FBRX) operate in?

Forte Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Forte Biosciences (FBRX) Stock Price, Quote, News & History

FBRXNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$29.27

0.050.17%

At close: Jan 30, 4:00 PM EST

$29.27

N/A

After Hours: Jan 30, 4:00 PM EST

Overview

News Earnings Options Analyst Ratings Insider Trades Short Interest Stock Report

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$28.95

Close

$29.27

Volume / Avg.

215.74K / 162.14K

Day Range

$26.66 - $29.37

52 Wk Range

4.90 - 35.62

Market Cap

$366.66M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

52

Short Interest

4.84%

Days to Cover

2.35

Recent Forte Biosciences Inc News

Why Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Why Forte Biosciences (FBRX) Stock Is Trading Lower

Forte Biosciences shares are trading lower by 13.6% Monday afternoon. The company announced plans for the periodic resale of up to 9.5 million common stock shares by selling stockholders.

Henry Khederian

Forte Biosciences Shares Are Soaring Today: What's Going On?

Forte Biosciences Inc. (NASDAQ: FBRX) shares are trading higher Wednesday. The company announced a $53 million private placement to fund the development of its autoimmune-focused drug candidate, FB102. Here's what you need to know.

Vaishali Prayag

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-44.43M

Investing Cash Flow (TTM)

247.00K

Financing Cash Flow (TTM)

121.23M

Free Cash Flow (TTM)

-44.57M

Capital Expenditure (TTM)

-147.00K

Net Change in Cash (TTM)

77.05M

Analyst Trends and Forecast

2

Aug 25

2

Nov 25

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$272.87M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

4.35

Earnings Yield % (TTM)

-0.27%

Earnings Yield % (FWD)

-9.32%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$6.71

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$93.41M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$28.95

Close

$29.27

Volume / Avg.

215.74K / 162.14K

Day Range

$26.66 - $29.37

52 Wk Range

4.90 - 35.62

Market Cap

$366.66M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

52

Short Interest

4.84%

Days to Cover

2.35

About

Sector

Health Care

Industry

Biotechnology

Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-v...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Forte Biosciences (FBRX) stock?

A

You can purchase shares of Forte Biosciences (NASDAQ:FBRX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Forte Biosciences (FBRX) competitors?

A

Other companies in Forte Biosciences’s space includes: Zura Bio Ltd (NASDAQ:ZURA), Tectonic Therapeutic Inc (NASDAQ:TECX), Burning Rock Biotech Ltd (NASDAQ:BNR), PepGen Inc (NASDAQ:PEPG) and AC Immune SA (NASDAQ:ACIU).

Q

What is the forecast, or price target, for Forte Biosciences (FBRX) stock?

A

Forte Biosciences has a consensus price target of $41.55.

Q

What is the current price for Forte Biosciences (FBRX)?

A

The stock price for Forte Biosciences (NASDAQ: FBRX) is $29.27 last updated January 30, 2026 at 4:00 PM EST.

Q

Does Forte Biosciences (FBRX) pay a dividend?

A

There are no upcoming dividends for Forte Biosciences.

Q

When is Forte Biosciences (NASDAQ:FBRX) reporting earnings?

A

Forte Biosciences does not have any upcoming earnings scheduled.

Q

Is Forte Biosciences (FBRX) going to split?

A

There is no upcoming split for Forte Biosciences.

Q

What sector and industry does Forte Biosciences (FBRX) operate in?

A

Forte Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Tectonic Therapeutic Inc

NASDAQ:TECX

$19.60

-1.95%

Burning Rock Biotech Ltd

Eupraxia Pharmaceuticals Inc

NASDAQ:EPRX

$8.28

%

Lineage Cell Therapeutics Inc

AMEX:LCTX

$1.50

1.35%

Assembly Biosciences Inc

NASDAQ:ASMB

$26.45

2.62%

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$28.95

Close

$29.27

Volume / Avg.

215.74K / 162.14K

Day Range

$26.66 - $29.37

52 Wk Range

4.90 - 35.62

Market Cap

$366.66M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

52

Short Interest

4.84%

Days to Cover

2.35

Recent Forte Biosciences Inc News

Why Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Why Forte Biosciences (FBRX) Stock Is Trading Lower

Forte Biosciences shares are trading lower by 13.6% Monday afternoon. The company announced plans for the periodic resale of up to 9.5 million common stock shares by selling stockholders.

Henry Khederian

Forte Biosciences Shares Are Soaring Today: What's Going On?

Forte Biosciences Inc. (NASDAQ: FBRX) shares are trading higher Wednesday. The company announced a $53 million private placement to fund the development of its autoimmune-focused drug candidate, FB102. Here's what you need to know.

Vaishali Prayag

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-44.43M

Investing Cash Flow (TTM)

247.00K

Financing Cash Flow (TTM)

121.23M

Free Cash Flow (TTM)

-44.57M

Capital Expenditure (TTM)

-147.00K

Net Change in Cash (TTM)

77.05M

Analyst Trends and Forecast

2

Aug 25

2

Nov 25

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$272.87M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

4.35

Earnings Yield % (TTM)

-0.27%

Earnings Yield % (FWD)

-9.32%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$6.71

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$93.41M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$28.95

Close

$29.27

Volume / Avg.

215.74K / 162.14K

Day Range

$26.66 - $29.37

52 Wk Range

4.90 - 35.62

Market Cap

$366.66M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

52

Short Interest

4.84%

Days to Cover

2.35

About

Sector

Health Care

Industry

Biotechnology

Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-v...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry